A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2018-08-09
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether VIB4920 (formerly MEDI4920) is safe and well tolerated in participants with adult-onset rheumatoid arthritis (RA).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Viela Bio

Criteria

Inclusion Criteria:

• adult-onset rheumatoid arthritis

• swollen and tender joints

Exclusion Criteria:

• venous thromboembolism or arterial thrombosis

• pregnant or breastfeeding

• positive hepatitis B, hepatitis C, and human immunodeficiency virus infection

• active or untreated latent tuberculosis